Hypertension:顽固性高血压的治疗 药物优于RDN

2014-03-07 高晓方 译 医学论坛网

挪威一项研究表明,在真正顽固性高血压(TRH)患者中,药物调整治疗的降压效果优于去肾交感神经(RDN)治疗。论文3月3日在线发表于《高血压》(Hypertension)。 此项研究共纳入19例TRH患者,并随机给予经导管实施的RDN或临床调整降压药物治疗。以经过包括利尿剂在内的3种最大耐受剂量降压药治疗后,诊室收缩压仍>140 mmHg定义TRH;将降压药监督应用后动态血压恢复正常

挪威一项研究表明,在真正顽固性高血压(TRH)患者中,药物调整治疗的降压效果优于去肾交感神经(RDN)治疗。论文3月3日在线发表于《高血压》(Hypertension)。

此项研究共纳入19例TRH患者,并随机给予经导管实施的RDN或临床调整降压药物治疗。以经过包括利尿剂在内的3种最大耐受剂量降压药治疗后,诊室收缩压仍>140 mmHg定义TRH;将降压药监督应用后动态血压恢复正常者排除在外。

结果显示,研究因RND降压效果不确定而提前终止。药物调整组患者的诊室收缩压和舒张压由基线时160±14/88±13 mmHg降至6个月时132±10/77±8 mmHg;RDN组患者则由156±13/91±15降至148±7/89±8 mmHg(SBP 和DBP 的P值分别为0.42和0.48)。6个月时,药物调整组患者的收缩压和舒张压均显著降低(P值分别为0.002和0.004),并且收缩压决定变化幅度大于RDN组。动态血压变化与诊室血压变化相一致。

原始出处:

Fadl Elmula FE1, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, Gjønnæss E, Hjørnholm U, Kjær VN, Rostrup M, Os I, Stenehjem A, Høieggen A.Adjusted Drug Treatment Is Superior to Renal Sympathetic Denervation in Patients With True Treatment-Resistant Hypertension.Hypertension. 2014 Mar 3.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1632844, encodeId=9eb7163284485, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sun Mar 30 16:11:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038483, encodeId=d9e420384834e, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat May 03 08:11:00 CST 2014, time=2014-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725577, encodeId=24091e25577ee, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 14 03:11:00 CST 2015, time=2015-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501037, encodeId=e7da150103ec9, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sun Mar 09 04:11:00 CST 2014, time=2014-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538747, encodeId=719a1538e47d8, content=<a href='/topic/show?id=89ec1519928' target=_blank style='color:#2F92EE;'>#RDN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15199, encryptionId=89ec1519928, topicName=RDN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e013034210, createdName=xsm922, createdTime=Sun Mar 09 04:11:00 CST 2014, time=2014-03-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1632844, encodeId=9eb7163284485, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sun Mar 30 16:11:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038483, encodeId=d9e420384834e, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat May 03 08:11:00 CST 2014, time=2014-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725577, encodeId=24091e25577ee, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 14 03:11:00 CST 2015, time=2015-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501037, encodeId=e7da150103ec9, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sun Mar 09 04:11:00 CST 2014, time=2014-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538747, encodeId=719a1538e47d8, content=<a href='/topic/show?id=89ec1519928' target=_blank style='color:#2F92EE;'>#RDN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15199, encryptionId=89ec1519928, topicName=RDN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e013034210, createdName=xsm922, createdTime=Sun Mar 09 04:11:00 CST 2014, time=2014-03-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1632844, encodeId=9eb7163284485, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sun Mar 30 16:11:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038483, encodeId=d9e420384834e, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat May 03 08:11:00 CST 2014, time=2014-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725577, encodeId=24091e25577ee, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 14 03:11:00 CST 2015, time=2015-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501037, encodeId=e7da150103ec9, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sun Mar 09 04:11:00 CST 2014, time=2014-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538747, encodeId=719a1538e47d8, content=<a href='/topic/show?id=89ec1519928' target=_blank style='color:#2F92EE;'>#RDN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15199, encryptionId=89ec1519928, topicName=RDN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e013034210, createdName=xsm922, createdTime=Sun Mar 09 04:11:00 CST 2014, time=2014-03-09, status=1, ipAttribution=)]
    2015-02-14 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1632844, encodeId=9eb7163284485, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sun Mar 30 16:11:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038483, encodeId=d9e420384834e, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat May 03 08:11:00 CST 2014, time=2014-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725577, encodeId=24091e25577ee, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 14 03:11:00 CST 2015, time=2015-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501037, encodeId=e7da150103ec9, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sun Mar 09 04:11:00 CST 2014, time=2014-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538747, encodeId=719a1538e47d8, content=<a href='/topic/show?id=89ec1519928' target=_blank style='color:#2F92EE;'>#RDN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15199, encryptionId=89ec1519928, topicName=RDN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e013034210, createdName=xsm922, createdTime=Sun Mar 09 04:11:00 CST 2014, time=2014-03-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1632844, encodeId=9eb7163284485, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sun Mar 30 16:11:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038483, encodeId=d9e420384834e, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat May 03 08:11:00 CST 2014, time=2014-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725577, encodeId=24091e25577ee, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 14 03:11:00 CST 2015, time=2015-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501037, encodeId=e7da150103ec9, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sun Mar 09 04:11:00 CST 2014, time=2014-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538747, encodeId=719a1538e47d8, content=<a href='/topic/show?id=89ec1519928' target=_blank style='color:#2F92EE;'>#RDN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15199, encryptionId=89ec1519928, topicName=RDN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e013034210, createdName=xsm922, createdTime=Sun Mar 09 04:11:00 CST 2014, time=2014-03-09, status=1, ipAttribution=)]
    2014-03-09 xsm922

相关资讯

睡眠质量差与顽固性高血压有关

一项新研究显示,睡眠质量差与女性顽固性高血压倍增有关,而其机制可能是由于抑郁介导的。上周在美国心脏协会高血压研究2012科学会议上,来自意大利Pisa大学的Rosa MariaBruno博士展示了这项研究。“虽然我们还需要更多的资料才能在临床上进行推广,但是我要说,治疗失眠可能会改善顽固性高血压。”Bruno对heartwire如是说。“有很多证据表明,睡眠障碍与心血管事件有关,但大多数是与睡眠障

Chest:限盐饮食或可缓解睡眠呼吸暂停

  澳大利亚昆士兰大学医学院Pimenta及其同事进行的一项研究表明,对于顽固性高血压和醛固酮增多症患者,膳食中盐的摄入量与其阻塞性睡眠呼吸暂停(OSA)严重程度有关。   OSA是高血压病(尤其是顽固性高血压病)与心血管疾病较强的独立危险因素,顽固性高血压患者的OSA患病率普遍较高,这一现象与此类患者醛固酮水平、盐摄入量以及血压的盐敏感性较高有关。   研究者使用夜间多导睡眠仪监

卢成志:顽固性高血压治疗现状

    高血压病在大多数患者并无特殊症状,因此容易被忽视,但是由其引起的脑卒中、心肌梗死等心脑血管疾病已成为我国的第一杀手,而且高血压还是中风、冠心病、心力衰竭和肾功能衰竭的主要危险因素。《中国高血压指南2010年修订版》、《中国心血管病防治指南》等指南的更新与修改,是根据国内外发表的相关资料,倚重循证医学证据并结合我国实际特点编写的,旨在推进心血管病的防治工作。顽固

阜外医院用新方法RSD攻克顽固性高血压

 国家心血管病中心阜外医院在国内率先使用经CE批准上市的去肾交感神经射频消融专用导管系统(Ardian公司生产Simplicity射频消融导管),为4名顽固性高血压患者实施了去肾交感神经射频消融术,手术过程顺利,手术圆满成功。这种新的顽固性高血压介入治疗技术在医学上称为经导管射频消融去肾交感神经术(Catheter-basedrenalsympatheticdenervation,简称R

沪瑞金经桡动脉肾交感神经消融治顽固高血压

由瑞金医院高血压科高平进教授和心脏科张瑞岩教授领衔的团队于11月14日在瑞金医院心导管室完成了国内首例经桡动脉肾交感神经消融治疗顽固性高血压,取得完满成功。 鉴于众多临床研究的良好结果,肾交感神经消融已成为国外目前治疗顽固性高血压的重要手段。但该领域在国内仍处于刚刚起步阶段,上海瑞金医院与北京阜外医院共同率先在国内开展了该领域的临床研究。 经过严格的患者筛选,上海瑞金医院高血压科和心脏内科团队

Circulation:在新发高血压患者中顽固性高血压者占2%

 《循环》(Circulation)杂志2月29日在线发布美国一项回顾性队列研究结果:对于新诊断的高血压患者,在18个月中,1/50的患者将发展为顽固性高血压(其定义为虽使用≥3种降压药仍不能控制血压);顽固性高血压患者的心血管事件风险显著增加,故对于这部分人群须给予更多关注以改善其高血压的转归。   澳大利亚布里斯班亚历山大公主医院皮门塔(Pimenta)医生和卡尔霍恩(Calhoun)医生